2024-03-29T13:32:31Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00001554
2022-12-15T04:35:46Z
453:454
482:483:484
Cardioprotective effects of recombinant human erythropoietin in rats with Experimental autoimmune myocarditis
Mitsuma, Wataru
Ito, Masahiro
Kodama, Makoto
Fuse, Koichi
Okamura, Kazuki
Minagawa, Shiro
Kato, Kiminori
Hanawa, Haruo
Toba, Ken
Nakazawa, Mikio
Aizawa, Yoshifusa
Elsevier Inc.
Erythropoietin
Experimental autoimmune myocarditis
Erythropoietin receptor
Apoptosis
Erythropoietin (EPO) has been known to have cytoprotective effects on several types of tissues, presumably through modulation of apoptosis and inflammation. The effect of EPO on myocardial inflammation, however, has not yet been clarified. We investigated the cardioprotective effects of EPO in rats with experimental autoimmune myocarditis (EAM). Seven-week-old Lewis rats immunized with cardiac myosin were treated either with EPO or vehicle and were examined on day22. EPO attenuated the functional and histological severity of EAM along with suppression of mRNAs of tumor necrosis factor (TNF)-a and interleukin (IL)-6 in the hearts as well as a reduction of apoptotic cardiomyocytes. The EPO receptor (EPO-R) was upregulated in the myocardium of EAM compared with that of healthy rats. These results may suggest that EPO ameliorated the progression of EAM by modulating myocardial inflammation and apoptosis.
Elsevier
2006-03
eng
journal article
VoR
http://hdl.handle.net/10191/1165
https://niigata-u.repo.nii.ac.jp/records/1554
http://doi.org/10.1016/j.bbrc.2006.03.230
AA00564395
0006-291X
Biochemical and Biophysical Research Communications
344
3
987
994
https://niigata-u.repo.nii.ac.jp/record/1554/files/24_0007.pdf
application/pdf
4.0 MB
2019-07-29